GGrantIndex
← Search

IDEC Y2B8 RADIOIMMUNOTHERAPY IN B CELL NON HODGKINS LYMPHOMA

$20,474M01FY2000RRNIH

Northwestern University, Evanston IL

Investigators

Linked publications & trials

Abstract

The current IDEC Pharmaceuticals protocol evaluating the efficacy and safety of IDEC-Y2B8 is a randomized study comparing Rituxan alone to Rituxan and radiolabelled monoclonal antibody therapy. It is restricted to patients who have platelet counts above 150,000. The proposed study IDEC 106-05 is a non-randomized study using Rituxan and IDEC Y2B8 for patients with platelet counts from 100-150,000.

View original record on NIH RePORTER →
IDEC Y2B8 RADIOIMMUNOTHERAPY IN B CELL NON HODGKINS LYMPHOMA · GrantIndex